<DOC>
	<DOC>NCT02111577</DOC>
	<brief_summary>The purpose of this study is to determine whether DCVAC/PCa added onto Standard of Care Chemotherapy can improve survival times for patients with Metastatic Castration Resistant Prostate Cancer.</brief_summary>
	<brief_title>Phase III Study of DCVAC Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>Male 18 years and older Histologically or cytologically confirmed prostate adenocarcinoma Presence of skeletal, and/or softtissue/visceral/nodal metastasis Disease progression despite Androgen Deprivation Therapy Maintenance of castrate conditions Life expectancy of at least 6 months based on InvestigatorÂ´s judgment. Eastern Cooperative Oncology Group (ECOG) Performance status 02 At least 4 weeks after surgery or radiotherapy A minimum of 28 days beyond initiation of bisphosphonate or denosumab therapy Recovery from primary local surgical treatment, radiotherapy or orchiectomy Confirmed brain and/or leptomeningeal metastases Current symptomatic cord compression requiring surgery or radiation therapy Prior chemotherapy for prostate cancer Subjects who are not indicated for chemotherapy treatment with first line Standard of Care chemotherapy (docetaxel and prednisone) Systemic corticosteroids at doses greater than 40mg hydrocortisone daily or equivalent for any reason other than treatment of prostate cancer (PCa) within the previous 6 months Systemic immunosuppressive therapy for any reason Treatment with immunotherapy against PCa within the previous 6 months prior to randomization Clinically significant cardiovascular disease Active autoimmune disease requiring treatment Uncontrolled comorbidities Participation in a clinical trial using experimental therapy within the last 4 weeks prior to randomization Participation in a clinical trial using immunological experimental therapy (e.g. monoclonal antibodies, cytokines or active cellular immunotherapies) within the last 6 months prior to randomization</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Immunotherapy</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Castrate Resistant</keyword>
	<keyword>Prostate Cancer</keyword>
	<keyword>Biological</keyword>
	<keyword>Vaccine</keyword>
</DOC>